Clinical Trial of Glatiramer Acetate in Amyotrophic Lateral Sclerosis (ALS)
Status:
Completed
Trial end date:
2008-06-17
Target enrollment:
Participant gender:
Summary
Teva is developing 40 mg/ml Glatiramer Acetate (GA) Injection , administered once daily under
the skin, for the treatment of ALS. The study drug is a higher dose formulation of Copaxone®
(20 mg/ml GA), a marketed medication, approved for the treatment of relapsing-remitting
multiple sclerosis. GA is an immunomodulating drug that has anti inflammatory and
neuroprotective properties, which are believed to be of therapeutic value in ALS. The study
treatment duration is 1 year (52 weeks).